News
Background: Ipilimumab and nivolumab (IPI-NIVO) and IO/vascular endothelial growth factor (VEGF) inhibitor combinations (IOVE) are now standard of care 1L treatment options for mRCC. However, there is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback